Bristol Myers Squibb's (NYSE:BMY) Growth Portfolio of newer drugs grew 12% to $7.7 billion in the third quarter, supplying nearly all of the company's 7% revenue gain. Shares were roughly flat in midday trading. Bristol now grows on its newer medicines. The drop in adjusted earnings reflects the cost of buying its next ones, not a weaker core business. Key Numbers What It Means
CryptoAlerta — análise de criptomoedas e mercado em tempo real